Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets

Nxera has exercised its option to license lucerastat for Japan, South Korea, Taiwan and selected other Asia Pacific markets (excluding China), paying Idorsia CHF 7 million upfront and contributing to the global Phase 3 program. Lucerastat is an investigational oral therapy for Fabry disease with more than 400 patient-years of clinical experience, adding a late-stage rare disease asset to Nxera's portfolio in Japan and Asia Pacific. Idorsia today initiated FAB-KLEAR, a pivotal Phase 3 study, as p